Global Health Ltd
NSE:MEDANTA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
903.15
1 487.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Global Health Ltd
Cost of Revenue
Global Health Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Global Health Ltd
NSE:MEDANTA
|
Cost of Revenue
-₹7.6B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Krishna Institute of Medical Sciences Ltd
NSE:KIMS
|
Cost of Revenue
-₹11.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Apollo Hospitals Enterprise Ltd
NSE:APOLLOHOSP
|
Cost of Revenue
-₹98.1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
F
|
Fortis Healthcare Ltd
NSE:FORTIS
|
Cost of Revenue
-₹16.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
|
Max Healthcare Institute Ltd
NSE:MAXHEALTH
|
Cost of Revenue
-₹11.2B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Narayana Hrudayalaya Ltd
NSE:NH
|
Cost of Revenue
-₹20.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Global Health Ltd
Glance View
Global Health Ltd. engages in the provision of healthcare, pathology, and other medical services. The company is headquartered in New Delhi, Delhi and currently employs 9,350 full-time employees. The company went IPO on 2022-11-16. Medanta delivers advanced, end-to-end healthcare in Delhi, Gurugram, Indore, Ranchi, Patna and Lucknow through its network of five hospitals, six Mediclinic, diagnostic laboratories, homecare and telemedicine services. The company provides treatments for coronary artery disease, head and neck cancer, acute myeloid leukemia, epilepsy, hip fracture, Parkinson's disease, refractive error, prostate cancer, chronic kidney disease, cerebral stroke, sepsis, liver cirrhosis, rheumatoid, arthritis, hypertension, diabetes, bronchial asthma, stomach cancer, and chronic otitis media. Medanta specializes in cardiac surgery, nephrology, urology, andrology, dermatology, ophthalmology, radiology and imaging, dental sciences, and interventional cardiology, among others. Its facilities and services include medicine delivery, air ambulance, patient support services, and others.
See Also
What is Global Health Ltd's Cost of Revenue?
Cost of Revenue
-7.6B
INR
Based on the financial report for Mar 31, 2024, Global Health Ltd's Cost of Revenue amounts to -7.6B INR.
What is Global Health Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-30%
Over the last year, the Cost of Revenue growth was -21%. The average annual Cost of Revenue growth rates for Global Health Ltd have been -30% over the past three years .
You don't have any saved screeners yet
